Evidence-based nutraceuticals for osteoarthritis: A review

Dr. Anish Desai, Parshuram Nivrutti Shendge and Dr. Sunaina S Anand

DOI: https://doi.org/10.22271/ortho.2021.v7.i2k.2713

Abstract
Osteoarthritis (OA) is a major cause of disability worldwide. Alternative treatments are preferred due to the cardiovascular and gastrointestinal side effects of non-steroidal anti-inflammatory drugs (NSAIDs). Nutraceuticals help in balancing anabolic and catabolic processes in the joint tissue, improve redox balance, free-radical scavenging, thus provide cartilage protection. The anti-inflammatory, chondroprotection and antioxidant action of nutraceuticals help in the modification of OA pathophysiology and prevent destruction of articulate cartilage. In this current review, we have highlighted many existing nutraceuticals that have good efficacy, safety & easy accessibility.

Keywords: osteoarthritis, nutraceuticals, anti-inflammatory, chondroprotection, antioxidant

Introduction
Osteoarthritis (OA) of the knee is a major cause of disability in older adults worldwide, with a prevalence of 28.7% in India. It affects the hands, feet, spine, and large weight-bearing joints, such as the hips and knees. Elderly, women, obesity, sedentary people and heavy lifting are few risk factors associated with OA of the knee [1, 2]. The onset of OA is a consequence of synovial inflammation influenced 5-lipoxygenase (5-LOX) pathway, proinflammatory cytokines and matrix metalloproteinases (MMPs) enzymatically degenerate cartilaginous matrix substances thereby aggravating the condition [3-5]. Failure of NSAIDS, viscosupplementation and intra-articular corticosteroids and other non-pharmacological interventions is attributed to a lack of efficacy and more adverse effects [6-9]. Alternative treatments are preferred due to the cardiovascular and gastrointestinal side effects of NSAIDs [10]. The ideal treatment should consist of therapeutic agent with capacity to modify natural pathophysiology of OA and modify destruction of articular cartilage. Nutraceuticals are described as food substances with medical & health benefits accompanied disease modifying action without any serious side effects. Nutraceuticals have a broad mechanism by inhibiting TNF-a, IL-1B, MMPs, NO, COX and caspases whereas NSAIDs only block arachidonic acid pathway and inhibit release of Cyclooxygenase [11].

Fig 1: Mechanism of nutraceuticals in osteoarthritis [12]
The objective of current review is to understand pathophysiology of OA and evaluated the efficacy and safety of nutraceuticals in their management.

**Omega-3 fatty acid**
Fish oil consists of omega-3 fatty acids, the most important ones being eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which are responsible for the variety of health benefits. Different in vitro & in vivo studies on fish oil displayed dose dependent decrease in inflammatory induced destruction of cartilage tissue. The mechanism of anti-inflammatory action involves competition of anti-inflammatory molecule resolvins; competition with receptors of pro-inflammatory molecules; interference in inflammatory signaling pathway; decline in lymphocyte proliferation; & gene expression of cyclo-oxygenase-2, cytokines [13].

**Clinical evidence:** A randomized double blind clinical trial was conducted to compare efficacy of high dose & low dose of fish oil in 202 patients with knee osteoarthritis. At the end of the study, low dose fish oil found to be more efficient than high dose fish oil in terms of WOMAC score & functional score [14]. More clinical studies are required to support the use of fish oil in treatment of OA.

**Olive Oil**
Phenolic compounds & monounsaturated fatty acids (MUFAs) are the bioactive ingredients of olive oil responsible for anti-inflammatory action. Preclinical studies showed improved cartilage recovery in olive oil fed rats after anterior cruciate ligament transection [15].

**Clinical evidence:** In a randomized, double blind clinical trial, olive water extract evaluated for 8 weeks and found significant improvement in terms of Health assessment questionnaire disability index & disease activity score with 28-joint count index [16]. Furthermore, the study was performed on Female (40-85 years) Iranian OA patient to examine effect of topical application of olive oil in comparison to 1 gm of piroxicam gel (0.5%). Piroxicam & olive oil decreased WOMAC score but olive oil found superior in the treatment after second week of treatment. The study had a high dropout rate, but rate was not significant between treatment and control group. In addition, the study was performed for short duration therefore long-term effect of olive oil needs to be evaluated further [17].

**Methionine**
Also known as essential amino acid as it is not synthesized inside the body & therefore needs to be consumed through diet. S-adenosylmethionine (SAME) which is active form of methionine has antioxidant properties & provides antioxidant enzyme glutathione peroxidase in the joint [18, 19]. Furthermore, SAMe also inhibits the enzyme system which degrades cartilages thereby protects proteins and proteoglycans. Research studies displayed that SMEs regulate cartilage regeneration by promoting anabolic process of cartilage [20].

**Clinical evidence**
The long-term use of SAME have produced more prominent effect in OA patients than NSAIDs [21]. Also, OA patients with liver & kidney disease have difficulty in methionine activation but supplementation with SAME proved to be effective [22]. The effect of methionine for symptomatic management of OA was evaluated in double blind cross over study involving sixty-one patient. The study compared of methionine (200mg) & celecoxib (200mg) for pain control, functional improvement & reduced side effects. Methionine displayed slower onset of action, but efficacy is similar to celecoxib in terms of pain reduction, improvement from the baseline & joint function test. However longer duration study required as onset of methionine action was allow compared to celecoxib [23]. Konig B 1987 performed a long term (24 months) multicenter trial to evaluate efficacy & tolerance of methionine in 108 OA patient. Methionine was well tolerated and showed good clinical efficacy in OA patient. Non-specific side effects occurred in 20 patients were disappeared during the therapy [24]. The clinical data suggest the use of methionine in the management of OA, however more clarity needed to understand molecular mechanism.

**Undenatured Type II Collagen**
It’s a nutritional supplement derived from sternum cartilage of chicken which increases mobility & functionality of joints with reduced pain in OA patient. [25, 26] It affects humoral and cellular immune response through T-cell thereby secreting cytokines which constrain response to collagen type II present in articulate cartilage. Undenatured type II collagen thereby inhibits over-reaction of pro-inflammatory immune system I OA patients [27, 28]. Despite of its efficacy in OA as it reduces pain and block inflammatory markers, still further investigation is recommended for safe use in human.

**Curcumin**
Curcumin is a polyphenol extracted from curcuma longa (Turmeric) known for its anti-inflammatory action since ancient time [29]. Curcumin exerts its anti-inflammatory action by interaction with NF-kB signaling pathway & reduces expression of inflammatory markers such as IL-1β, TNF-alpha, COX-2 and MMP [30]. Furthermore, Curcumin upregulates the production of collagen-II and decreases MMP13 expression, thus inhibiting NF-kB pathway [31, 32]. Curcumin also exert its anti-inflammatory and antioxidant effect by acting on pathways involving reactive oxygen species, Nrf2 and its target genes such as superoxide dismutase (SOD2), HO-1, and glutamate cysteine ligase catalytic subunit. It also promotes autophagy by attenuating Akt/mTOR pathway leading to reduced apoptosis and matrix degradation [33].

**Clinical evidence**: Safety & efficacy of curcumin in OA was compared with diclofenac in a randomized open label study. At the end of study, patient receiving curcumin exhibited similar improvement to that of diclofenac in pain & Knee Injury and Osteoarthritis Outcome Score. In addition to that, none of the curcumin treated patient required H2 blockers. Also, low side effects were observed in curcumin group when compared with diclofenac. The study suggest curcumin can be used as an alternative treatment in OA patient with side effects of NSAIDs [34]. In another study, Horyan et al. 2018 evaluated combination of curcumin & boswellic acid extract in 201 OA patients. After 12-week study, combination found to be effective in pain reduction & improves physical function of participants [35].

**Quercetin**
It is a circulating aglycone form of rutin widely available in vegetables with strong ROS scavenging activity [36]. The Chinese traditional medicine identified quercetin as herbal
treatment in OA patient. Different in vivo studies evaluated the role of quercetin in OA & found beneficial by both routes using topical application as well as oral supplementation. The polyphenols act by promoting mitochondrial biogenesis and efficiency by improving potential of membrane, oxygen consumption, ATP production, glutathione levels & decreasing oxidative stress. These effects found to be mediated by phosphorylation of AMPK & increased expression of SIRT-1 which leads to attenuation of ER stress in rat OA models thereby improves maintenance of cartilages & chondrocyte survival. Quercetin also found to reduce accumulated synovial M1 macrophages which endure OA exacerbation in human & animal. Furthermore, quercetin also improves TGF-β & insulin like growth factor expression which stimulate prochondrogenic environment & CAF synthesis in chondrocytes thereby improves repairing capacity of cartilage.

Glycosaminoglycans (CAGs)
Chondroitin Sulfate (CS), Glucosamine Sulfate (GS) and hyaluronic acids are glycosaminoglycans (CAGs) produced by chondrocytes and synoviocytes and are vital component of extracellular matrix and synovial fluid. Growing evidence suggest that supplementation with CAGs protects joints from trauma or wear and ultimately protect from OA progression. Supplementation with glucosamine sulfate stimulate cartilage regeneration along with improvement in joint function and reduces pain which help in OA treatment. Although not all clinical papers are in favor of beneficial role of glucosamine in OA but large number of studies revealed that its low toxicity makes it able option in the treatment of OA.

Clinical evidence: In a randomized controlled trial, glucosamine sulfate & chondroitin sulfate improved catabolic & degenerative process in OA patient owing to their antioxidant & anti-inflammatory action. Jackson et al. in a pharmacokinetic study evaluated synergistic effect of glucosamine & chondroitin and found that both has no synergistic effect as they compete for intestinal absorption. Therefore, different time is used for ingestion of these two CAGS depend on individual clinical cases. Glucosamine sulfate & chondroitin sulfate improves pain and stiffness in OA patient when administered with fish oil containing n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Another CAGs, hyaluronic acid have showed beneficial effect in joint pain. During In vitro study hyaluronic acid improved mechanical properties of synovial fluid. It is generally used as local injection into the joint which reduces pain and improves function of OA patient. Clinical evidence suggests the efficacy of CAGs in the OA treatment, however further investigation is required to understand its anti-inflammatory action at the molecular level. The safety & efficacy of chondroitin sulfate (400 mg) & glucosamine hydrochloride (500 mg) was evaluated in knee osteoarthritic patient for 6 months. Combination possesses similar potency as that of celecoxib (200 mg) & reduced joint swelling, pain, stiffness in OA patient. The combination has comparable efficacy to celecoxib with excellent safety profile. In another two-year randomized follow-up study, 605 knee OA patients were evaluated for reduction in joint space narrowing (JSN) and pain after administration of glucosamine sulfate & chondroitin sulfate combination. These dietary supplements when administered in combination found to be effective significantly in reduction of JSN.

Wogonin
It is O-methylated flavone obtained from Scutellaria baicalensis and used in Chinese traditional medicine in the treatment of different disorder. Anti-inflammatory action of wogonin evaluated and found to be useful in reduction of MMP-3 expression in IL-1β treated articular chondrocytes. It also suppresses IL-1β induced activator protein-1 (AP-1) thereby controls chemokine expression. Wogonin also have ability to reduce reactive oxygen species generation in OA chondrocytes and induces Nrf2 and enzymes involved in antioxidant pathways. From in silico molecular docking study, it was observed that wogonin intercalates between guanine & cytosine bases as ethidium bromide and prevents denaturation of DNA and contribute to DNA stability. This evidence has been evaluated for topical application of wogonin in DMM mouse model of OA and found that topical wogonin improves joint health by reducing pathological scores which is mediated through MMP-13, NF-kB. More extensive long term clinical trials are required to determine safety & efficacy of wogonin in human.

Botanical extracts
Various botanical extract and their active components possess anti-inflammatory action and are currently evaluated for their action in OA.

Avocado & soybean
Avocado/soy unsaponifiable (ASU) components of avocado & soybean possess anabolic as well as anti-inflammatory on chondrocytes. In vitro studies revealed ASU blocks inflammatory cytokines such as IL-1, IL-8, IL-6 and prostaglandin E2. It also helps in stimulation of growth factor production, synthesis of collagen and aggregan. Daily administration of 300 mg of ASU improves OA symptoms, however further study required for better understanding of its mechanism in OA.

Green tea
It is non-fermented & one of the most consumed hot beverage which mainly consists of catechin, a powerful antioxidant. Polyphenols such as Epigallocatechin-3-gallate (EGCG) present in green tea significantly decreases advanced glycation end products responsible for pro-inflammatory responses in chondrocytes. EGCG also prevents expression of TNF-alpha, NF-kB, MMP-13 and proved its ability of inhibition of inflammatory response of OA by modulating RNA expression. Currently sufficient data is available for green tea’s action as an anti-inflammatory & anti-arthritic agent in preclinical model however further clinical research required to establish its efficacy in OA treatment.

Clinical evidence: Green tea is a dietary supplement and novel functional food with high polyphenol contents responsible for anti-inflammatory & bone repair action. The safety & efficacy of green tea extract was evaluated in 50 patients of OA & found significant reduction in VAS pain, total WOMAC & WOMAC physical function score.

Boswellia
Boswellia showed efficacy against different disease like cancers, inflammatory, wound healing etc. It is a gum resin extracted from Boswellia serrate & possess potent anti-inflammatory, analgesic & anti-arthritic activity. Studies revealed that 3-O-Acetyl-11-keto-beta-boswellic acid
(AKBA) which is active constituent of Boswellia extract inhibit 5-lipoxygenase and associated cellular inflammatory reactions. It also inhibits generation of pro-inflammatory cytokines which are involved in the process of cartilage damage. In another study, Blain et al showed that Boswellia not only reduces MMP-9 & MMP-3 m RNA levels but also inhibit expression of MMP9. Furthermore, Boswellia also decreases production of nitrite, prostaglandin E2 and cyclooxygenase-2. The novel Boswellia extract called as 5-Loxin consists of 30% of 3-O-acetyl-11-keto-boswellic acid (AKBA) found efficient and safe in OA patient. It significantly reduced MM-3 of synovial fluid in OA patient. Belcaro G et al. found that in OA patient WOMAC score for pain, stiffness and physical function is significantly improved after 4 weeks in Boswellia group when compared with control. In randomized double blind controlled study, 5-Loxin & Aflapin from Boswellia showed substantial improvement in pain and physical function of OA patient. In vitro and in vivo clinical evidence encourages the use of Boswellia still existing data suggest further investigation.

Ginger
Ginger possess anti-inflammatory activity which helps in treatment of OA by reducing inflammatory markers such as nitric oxide and C-reactive protein. Ginger supplementation along with diclofenac found efficient than individual treatment in OA patient. In another study, Amorndoljai et al evaluated topical application of ginger and showed efficacy in relieving joint pain and improves quality of life in patient. Furthermore, ginger also improves pain relief in patient who demonstrated poor response to NSAIDs. Current data suggest that ginger extract have limited efficacy, but results obtained from them are strong enough to encourage & support further evaluation in OA treatment.

**Clinical evidence:** Ginger is an ancient medicinal plant native to Asia & used in the treatment of different disease. Mozaffari-Khosravi et al., 2016 investigated effect of ginger powder on proinflammatory factors of OA patient in 3 months randomized double blind placebo-controlled trial. Serum levels of proinflammatory cytokines such as TNF-α & interleukin-1β found to be reduced at the end of the study. However, further investigation was recommended for evaluation of ginger in OA.

**Harpagophytum procumbens (Devils Claw)**
A South African plant Harpagophytum procumbens known as devils claw contains harpagosides-triterpene glycoside which found to be effective in reduction of IL-1β induced production of metalloproteinases (MMP-1, MMP-3 and MMP-9) in chondrocytes also down regulate TNF-alpha and COS-2 gene expression. Another study, Deeds claw extract when used as dietary supplement in the treatment of hip & knee OA patient found to be effective with low adverse effects such as diarrhea and flatulence. For further use, high quality clinical trials are required to determine the efficacy and safety of devils claw.

**Table 1:** Clinical trials of nutraceuticals in Osteoarthritis patient

| Nutraceutical           | Dose & comparator | Design & duration | Results                                      | Reference          |
|-------------------------|-------------------|-------------------|---------------------------------------------|--------------------|
| Fish oil                | high-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day or low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day | DB 24 months       | Greater improvement WOMAC score & function score in OA patient with low dose | Hill C.L. et al., [14] |
| Olive oil               | 400 mg of olive oil | DB 8 weeks        | decreased pain and improvement in activities of daily living | Bitler C. M. et al., [16] |
|                         | Topical olive oil & piroxicam gel | DB 4 weeks | WOMAC score improved in olive oil group after 2 weeks compared to piroxicam | Bohlooli et al. [17] |
| Methionine              | Methionine 200 mg & celecoxib 200 mg | DB 16 weeks | Pain reduction, improvement from baseline | Naim et al., [22] |
|                         | Methionine (200 +400 mg) | MC 24 months | Well tolerated & good clinical efficacy | Konig, 1987. [24] |
| Glycosaminoglycans      | chondroitin sulfate (400mg) plus glucosamine hydrochloride (500mg) & 200 mg celecoxib | DB; MC 6 months | Reduces pain, stiffness, joint swelling | Hochbers et al. [52] |
|                         | glucosamine sulfate & chondroitin sulfate | DB 2 years | reduced joint space narrowing (JSN) and pain | Fransen et al. [53] |
| Curcumin                | Curcumin 500 mg & diclofenac 50 mg | DB 28 days | Similar efficacy & better tolerance | Shep et al. [134] |
| Curcumin & Boswellic acid | 350 mg curcuminoinds and 150 mg boswellic acid | Phase II 12 weeks | Improved WOMAC joint pain index | Haryon et al. [35] |
| Green tea               | Green tea tablet 1500 mg & diclofenac 100 mg/day | R; open-label 4 weeks | reduction inVAS pain, total WOMAC & WOMAC physical function score | Hashempur et al. [64] |
| Ginger                  | Ginger 500mg/day | Double blind; 3 months | Reduced pro-inflammatory markers | Niempoog et al 2012 |
**Table 2: Pharmacological actions of nutraceutical in Osteoarthritis (Action: none “−”, Low “+”, Moderate “+++”, High “++++”**

| Nutraceuticals          | Anti-inflammatory | Anti-Oxidant | Anabolic | Anti-catabolic | Structural substrate | References |
|-------------------------|------------------|--------------|----------|----------------|----------------------|------------|
| Fish oil                | +++              | -            | -        | +              | ++                   | [13,19]    |
| CAGs                    | +                | +            | ++       | ++             | ++                   | [42,44]    |
| Olive oil               | +++              | +            | ++       | -              | +                    | [15,19]    |
| Methionine              | -                | +++          | +        | +              | ++                   | [18,20]    |
| Undenatured collagen    | +                | +            | +++      | ++             | ++                   | [25,26]    |
| Curcumin                | +++              | +++          | +        | +              | -                    | [40]       |
| Quercetin               | +                | +++          | -        | -              | -                    | [39,40]    |
| Wogonin                 | +++              | +            | -        | -              | ++                   | [56,57]    |

**Botanical Extracts**

| Avocado/soy unsaponifiables (ASU) | +++ | + | - | - | ++ | [59,60] |
| Green Tea                      | ++ | +++ | - | - | +  | [62,63] |
| Boswellia                      | +++ | + | - | - | ++ | [67,68] |
| Ginger                         | ++ | + | - | - | +  | [71,74] |
| Devils Claw                    | ++ | ++ | + | + | ++ | [78,78] |

**Conclusion**

The efficacy of nutraceuticals in OA is attributed to their anti-inflammatory, antioxidant, immunomodulatory and chondroprotective action. Nutraceuticals discussed in this current review are beneficial for relieving joint pain and improving quality of life. Scientific validation from different studies demonstrate that nutraceuticals not only improve clinical symptoms but also slow down progression of disease. Healthcare professionals must be made aware about the evidence-based efficacy and safety of certain nutraceuticals for OA. Due to their good efficacy and safety profile, nutraceuticals may be used in combination with conventional therapy for the management of OA.

**References**

1. Kumar H, Pal CP, Sharma YK, Kumar S, Uppal A. Epidemiology of knee osteoarthritis using Kellgren and Lawrence scale in Indian population. Journal of Clinical Orthopaedics and Trauma, 11 [Preprint]. 2020, S125-S129. https://doi.org/10.1016/j.jcot.2019.05.019
2. Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian Journal of Orthopaedics, 2016;50(5):518-522. https://doi.org/10.4103/0019-5413.189608
3. Westacott CI, Urban JP, Goldring MB, Elson CJ. The effects of pressure on chondrocyte tumour necrosis factor receptor ex-pression. Biochemistry 2002;39:125-132.
4. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cyto-kines in osteoarthritis pathophysiology. Biochiracology 2002;39:237-246.
5. Dijkgraaf LC, de Bont LG, Boeringer G, Liem RS. The structure, biochemistry, and metabolism of osteoarthritic cartilage: A review of the literature. J Oral Maxillofac Surg 1995;53:1182-1192.
6. Filardo G, Kon E, Longo UG, Madry H, Marchettini P, Marmotti A, et al. Non-surgical treatments for the management of early osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy 2016;24(6):1775-1785. https://doi.org/10.1007/s00167-016-4089-y
7. Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individ-uals. The American Journal of Hospice & Palliative Care 2014;31(5):562-575. https://doi.org/10.1177/1049909113494748
8. Kalunian KC. Current advances in therapies for osteoarthritis. Current Opinion in Rheumatology 2016;28(3):246-250. https://doi.org/10.1097/BOR.0000000000000273
9. Bennell KL, Hunter DJ, Hinman RS. Management of osteoarthritis of the knee. BMJ 2012;345:e4934. https://doi.org/10.1136/bmj.e4934
10. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. Annals of Internal Medicine 2015;162(1):46-54. https://doi.org/10.7326/M14-1231
11. Ravalli S, Szychlinska MA, Leonardi RM, Musumeci G. Recently highlighted nutraceuticals for preventive management of osteoarthritis. World Journal of Orthopaedics 2018;9(11):255-261. https://doi.org/10.5312/wjo.v9.i11.255
12. Leong DJ, Choudhury M, Hirsh DM, Hardin JA, Cobelli NJ, Sun HB. Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis. International journal of molecular sciences. 2013;14(11):23063-85.
13. Boe C, Vangsness CT. Fish oil and osteoarthritis: Current evidence. Am J Orthop. 2015;44:302-305.
14. Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K et al. Fish oil in knee osteoarthritis: A randomised clinical trial of low dose versus high dose. Ann. Rheum. Dis. 2016;75:23-29.
15. Musumeci G, Trovato FM, Pichler K, Weinberg AM, Loreto C, Castrogiovanni P. Extra-virgin olive oil diet and mild physical activity prevent cartilage degeneration in an osteoarthritis model: An in vivo and in vitro study on lubricin expression. J Nutr. Biochem. 2013;24:2064-2075.
16. Bitler CM, Matt K, Irving M, Hook G, Yusen J, Eager F, et al. Olive extract supplement decreases pain and improves daily activities in adults with osteoarthritis and decreases plasma homocysteine in those with rheumatoid arthritis. Nutrition Research 2007;27(8):470-477.
17. Bohlooli S, Jastan M, Nakhostin-Roohi B, Mohammadi S, Baghaei Z. A pilot double-blinded, randomized, clinical trial of topical virgin olive oil gel versus piroxicam gel in osteoarthritis of the knee. J Clin. Rheumatol. 2012;18:99-101.
18. Lieber CS, Packer L. S-Adenosylmethionine: Molecular, biological, and clinical aspects: An introduction. Am. J Clin. Nutr. 2002;76:1148S-1150S.
19. Lopez HL. Nutritional interventions to prevent and treat
osteoarthritis Part II: Focus on micronutrients and supportive nutraceuticals. PM R 2012;4:S155-S168.

20. Hosea Blewett HJ. Exploring the mechanisms behind S-adenosylmethionine (SAME) in the treatment of osteoarthritis. Crit. Rev. Food Sci. Nutr. 2008;48:458-463.

21. Kon E, Filardo G, Drobinic M, Madry H, Jelic M, van Dijk N et al. Non-surgical management of early knee osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 2012;20:436-449.

22. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-Adenosyl methionine versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. BMC Musculoskelet. Disord 2004;5:6.

23. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAME) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet. Disord. 2004;26:5:6

24. König B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83(5A):89-94.

25. Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undeveloped type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study. Nutr. J. 2016;15:14.

26. Gupta RC, Canerdy TD, Lindley J, Konemann M, Minniear J, Carroll BA et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II®), glucosamine and chondroitin in arthritic dogs: Pain evaluation by ground force plate. J Anim. Physiol. Anim. Nutr. 2012;96:770-777.

27. Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J et al. Oral administration of type-II collagen peptide 250–270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin. Immunol. 2007;122:75-84.

28. Park KS, Park MJ, Cho ML, Kwok SK, Ju JH, Ko HJ. Et al. Type II collagen oral tolerance: Mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod. Rheumatol 2009;19:581-589.

29. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M et al. Biological actions of curcumin on articular chondrocytes. Osteoarthr. Cartil. 2010;18:141-149.

30. Yang Q, Wu S, Mao X, Wang W, Tai H. Inhibition effect of curcumin on tnf-alpha and mmp-13 expression induced by advanced glycation end products in chondrocytes. Pharmacology 2013;91:77-85.

31. Wang J, Ma J, Gu JH, Wang FY, Shang XS, Tao HR, Wang X. Regulation of type ii collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1beta is mediated by curcumin via inhibition of nf-kappab signaling in rat chondrocytes. Mol. Med. Rep. 2017;16:1837-1845.

32. Yan D, He B, Guo J, Li S, Wang J. Involvement of tir8 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis. Acta Cir. Bras 2019;34:e201900604.

33. Jiang C, Luo P, Li X, Liu P, Li Y, Xu J. Nrf2/are is a key pathway for curcumin-mediated protection of tmj chondrocytes from oxidative stress and inflammation. Cell Stress Chaperones 2020;25:395-406.

34. Shep D, Khanwellkar C, Gade P, Karad S. Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study. Trials 2019;20(1):214.

35. Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med. 2018;18(1):7.

36. Sakanashi Y, Oyama K, Matsui H, Oyama TM, Nishimura Y et al. Possible use of quercetin, an antioxidant, for protection of cells suffering from overload of intracellular ca2+: A model experiment. Life Sci. 2008;83:164-169

37. Mok SW, Fu SC, Cheuk YC, Chu IM, Chan KM, Qin L, et al. Intra-articular delivery of quercetin using thermosensitive hydrogel attenuate cartilage degradation in an osteoarthritis rat model. Cartilage 2018, 1947603518796550.

38. Permatasari DA, Karliana D, Iskandarsyah I, Arsianti A, Bahtiar A. Quercetin prevent proteoglycan destruction by inhibits matrix metalloproteinase-9, matrix metalloproteinase-13, a disintegrin and metalloproteinase with thrombospondin motifs-5 expressions on osteoarthritis model rats. J Adv. Pharm. Technol. Res. 2019;10:2-8.

39. Feng K, Chen Z, Pengcheng L, Zhang S, Wang X. Quercetin attenuates oxidative stress-induced apoptosis via sirt1/ampk-mediated inhibition of er stress in rat chondrocytes and prevents the progression of osteoarthritis in a rat model. J Cell. Physiol 2019;234:18192-18205

40. Zhang H, Lin C, Zeng C, Wang Z, Wang H, Lu J et al. Synovial macrophage m1 polarisation exacerbates experimental osteoarthritis partially through r-spondin-2. Ann. Rheum. Dis. 2018;77:1524-1534.

41. Hu Y, Gui Z, Zhou Y, Xia L, Lin K, Xu Y. Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization tom2macrophages. Free Radic. Biol. Med. 2019;145:146-160

42. Kirkham SG, Samarasinghe RK. Review article: Glucosamine. J Orthop. Surg. 2009;17:72-76.

43. Henrotin Y, Mobasher A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res. Ther. 2012;17:201.

44. Michel BA, Stucki G, Frey D, de Vathaire F, Vignon E, Bruehlmann P et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum. 2005;52:779-786.

45. Kahan A, Uebelhart D, de Vathaire F, Delmas P, Reginster JY. Long-term effects of chondroitin sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-533

46. Jackson CG, Plaa AH, Sandy JD, Hua C, Kim-Rolands S, Barnhill JG et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010;19:297-302

47. Henrotin Y, Mobasher A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res. Ther. 2012;17:201
48. Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv. Ther. 2009;26:858-871.

49. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J Med 2006;354:795-808.

50. Maneiro E, de Andres MC, Ferández-Sueiro JL, Galdo F, Blanco FJ. The biological action of hyaluronan on human osteoarthritic articular chondrocytes: The importance of molecular weight. Clin. Exp. Rheumatol 2004;22:307-312.

51. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of knee osteoarthritis. Drug Saf 2000;23:115-130.

52. Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N et al. MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75(1):37-44.

53. Fransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S et al. LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2015;74(5):851-8.

54. Park JS, Lee HJ, Lee DY, Jo HS, Jeong JH, Kim DH et al. Chondroprotective effects of wogonin in experimental models of osteoarthritis in vitro and in vivo. Biomol. Ther 2015;23:442-448.

55. Khan NM, Haseeb A, Ansari MY, Haqqi TM. A wogonin-rich-fraction of scutellaria baicalensis root extract exerts chondroprotective effects by suppressing il-1beta-induced activation of ap-1 in human oa chondrocytes. Sci. Rep 2017;7:43789.

56. Khan NM, Haseeb A, Ansari MY, Devarapalli P, Haynie S, Haqqi TM. Wogonin, a plant derived small molecule, exerts potent anti-inflammatory and chondroprotective effects through the activation of ros/erk/tnf alpha signaling pathways in human osteoarthritic chondrocytes. Free Radic. Biol. Med. 2017;106:288-301.

57. Khan NM, Ahmad I, Ansari MY, Haqqi TM. Wogonin, a natural flavonoid, intercalates with genomic DNA and exhibits protective effects in il-1beta stimulated osteoarthritic chondrocytes. Chem. Biol. Interact. 2017;274:13-23.

58. Smith JF, Starr EG, Goodman MA, Hanson RB, Palmer TA, Woolstenhulme JB et al. Topical application of wogonin provides a novel treatment of knee osteoarthritis. Front. Physiol 2020;11:80.

59. Lippiello L, Nardo JV, Harlan R, Chioi T. Metabolic effects of avocado/soy unsaponifiables on articular chondrocytes. Evid. Based Complement. Altern. Med. 2008;5:191-197.

60. Henrotin YE, Sanchez C, Deberg MA, Piccardi N, Guillou GB, Msika P et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003;30:1825-1834.

61. Singh R, Akhtar N, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. Life Sci 2010;86(25-26):907-918.

62. Rasheed Z, Anbazhagan AN, Akhtar N et al. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009;11(3):R71.

63. Rasheed Z, Rasheed N, Al-Shaya O. Epigallocatechin-3-O-gallate modulates global micro RNA expression in interleukin-1βstimulated human osteoarthritis chondrocytes: potential role of EGCG on negative regulation of microRNA-140-3p and ADAMTS5. Eur J Nutr 2017.

64. Hashempur MH, Sadrneshin S, Mosavat SH, Ashraf A. Green tea (Camellia sinensis) for patients with knee osteoarthritis: A randomized open-label active-controlled clinical trial. Clin Nutr 2018;37(1):85-90.

65. Ammon HP. Boswellic Acids and Their Role in Chronic Inflammatory Diseases. Adv Exp Med Biol. 2016;928:291-327.

66. Sailer ER, Subramanian LR, Rall B et al. Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements or binding and 5- lipoxigenase inhibitory activity. Br J Pharmacol. 1996;117:615-618.

67. Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of proinflammatory molecules in articular cartilage. Phytotherapy Res 2010;24(6):905-12.

68. Sengupta K, Alluri KV, Satish AR et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008;10(4):R85.

69. Belcaro G, Dugall M, Luzzi R, et al. FlexiQule (Boswellia extract) in the supplementary management of osteoarthritis: a supplement registry. Minerva Med. 2014;105(6 Suppl 2):9-16.

70. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative Efficacy and Tolerability of 5-Loxin® and Aflapin® Against Osteoarthritis of the Knee: A Double-Blind, Randomized, Placebo-Controlled Clinical Study. Int J Med Sci. 2010;7(6):367-377.

71. Naderi Z, Mozaffari-Khosravi H, Dehghan A et al. Effect of ginger powder supplementation on nitric oxide and C-reactive protein in elderly knee osteoarthritis patients: A 12-week double-blind, randomized placebo-controlled clinical trial. J Trad Comp Med. 2015;6(3):199-203.

72. Mozaffari-Khosravi H, Naderi Z, Dehghan A, et al. Effect of Ginger Supplementation on Proinflammatory Cytokines in Older Patients with Osteoarthritis: Outcomes of a Randomized Controlled Clinical Trial. J Nutr Gerontol Geriatr 2016;35(3):209-18.

73. Amorndolpaj T, Tanepeanichskul S, Niempoog S, et al. Improving of Knee Osteoarthritic Symptom by the Local Application of Ginger Extract Nanoparticles: A Preliminary Report with Short Term Follow-Up. J Med Assoc Thai 2015;98(9):871-7.

74. Rondonelli M, Riva A, Morazzoni P et al. The effect and safety of highly standardized Ginger (Zingiber officinale) and Echinacea (Echinacea Angustifolia) extract supplementation on inflammation and chronic pain in NSAIDs poor responders. A pilot study in subjects with knee arthrosis. Nat Prod Res 2017;31(11):1309-1313.

75. Schulze-Tanzil G, Hansen C, Shakibaei M. Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro.
76. Fiebich BL, Muñoz E, Rose T, Weiss G, McGregor GP. Molecular targets of the anti-inflammatory Harpagophytum procumbens (Devil’s claw): Inhibition of TNF-α and COX-2 gene expression by preventing activation of AP-1. Phytother. Res. 2011;10:36-45.

77. Wegener T, Lupke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil’s claw (Harpagophytum procumbens DC). Phytother. Res. 2003;17:1165-1172.

78. Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complementary and Alternative Medicine 2004;4(1):1-0.